2020-10-27T10:53:08Z
2020-10-27T10:53:08Z
2019-07-23
2020-10-27T10:53:08Z
Background: Parkinson's disease (PD) is characterized by the loss of midbrain dopaminergic neurons (DAn). Previously, we described the presence of DNA hyper- and hypo-methylation alterations in induced pluripotent stem cells (iPSC)-derived DAn from PD patients using the Illumina 450K array which prominently covers gene regulatory regions. Methods: To expand and contextualize previous findings, we performed the first whole-genome DNA bisulfite sequencing (WGBS) using iPSC-derived DAn from representative PD subjects: one sporadic PD (sPD) patient, one monogenic LRRK2-associated PD patient (L2PD), and one control. Results: At the whole-genome level, we detected global DNA hyper-methylation in the PD which was similarly spread across the genome in both sPD and L2PD and mostly affected intergenic regions. Conclusion: This study implements previous epigenetic knowledge in PD at a whole genome level providing the first comprehensive and unbiased CpG DNA methylation data using iPSC-derived DAn from PD patients. Our results indicate that DAn from monogenic or sporadic PD exhibit global DNA hyper-methylation changes. Findings from this exploratory study are to be validated in further studies analyzing other PD cell models and patient tissues.
Artículo
Versión publicada
Inglés
Malaltia de Parkinson; ADN; Metilació; Parkinson's disease; DNA; Methylation
BioMed Central
Reproducció del document publicat a: https://doi.org/10.1186/s13148-019-0701-6
Clinical Epigenetics, 2019, vol. 11
https://doi.org/10.1186/s13148-019-0701-6
info:eu-repo/grantAgreement/EC/FP7/311736/EU//PD-HUMMODEL
cc-by (c) Fernández Santiago, Rubén et al., 2019
http://creativecommons.org/licenses/by/3.0/es